基于神经递质的机器学习模型,用于区分阿尔茨海默病和轻度认知障碍
Jiaxi Zhao1,2, Zhichuang Qu3, Zheng Li1,2
1The Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, China.
The Journal of international medical research
|January 13, 2026
概括
阿尔茨海默病和轻度认知障碍涉及与神经递质变化相关的脑缩. 机器学习模型准确地区分这些情况,有助于早期诊断和分期.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 机器学习 机器学习
背景情况:
- 阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 的特征是大脑缩.
- 神经递质系统的改变及其与AD/MCI灰质缩的联系尚未完全理解.
研究的目的:
- 研究灰色质缩和AD和MCI中神经递质分布之间的关系.
- 开发机器学习 (ML) 模型,使用灰质-神经递质共同定位来进行疾病分类.
主要方法:
- 在262名参与者 (AD,MCI,对照) 上使用了结构性MRI和基于voxel的形态测量.
- JuSpace工具箱评估了灰质缩和13个神经递质地图之间的空间相关性.
- 一个随机森林ML模型使用嵌套交叉验证进行了训练和验证.
主要成果:
- 在AD和MCI中观察到时间,额头和环膜区域的灰质损失.
- 与血清,多巴胺和谷氨酸系统相关的缩.
- 在MCI中降低受体-灰质相关性与抑郁症得分有关.
结论:
- 神经递质相关的灰质变化是AD和MCI病理学的组成部分.
- 开发的ML模型在区分AD和MCI方面显示出高准确度.
- 这种方法对神经退行性疾病的早期诊断和疾病分期有希望.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.7K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.7K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Dementia
515
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
515
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
552
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
552
Role of Neurotransmitters in Memory
2.5K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.5K
